We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Cutting-Edge Diagnostic Products and Solutions

By LabMedica International staff writers
Posted on 23 Jul 2023

Randox Laboratories (Crumlin, UK) is exhibiting its cutting-edge diagnostic products and solutions at 2023 AACC, while also highlighting its groundbreaking technologies. More...

As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including quality control, molecular diagnostics, third-party reagents, point of care, and clinical chemistry analyzers. With an extensive product range offering expansive third-party quality controls and calibrators, inter-laboratory data management, external quality assessments, and calibration verification. Randox’s new Acusera Quality Controls for 2022/2023 highlighted at the show include Active B12, Anti Mullerian Hormone (AMH), Brain Natriuretic Peptide (BNP) Control, Bone Markers (Serum) Control, Pre-eclampsia Control, Serum Indices Control, Ultra-Low PSA Control, Xanthochromia Control.

At AACC 2023, Randox is also showcasing its recently launched and the world’s first Xylazine ELISA. Xylazine, which is an analgesic drug primarily used within the veterinary industry as a tranquilizer, has not been approved for human use but has been linked to the USA’s illicit drug supply in recent years. While the prevalence of Xylazine is showing no sign of decreasing, Randox Toxicology continues to lead in new test development within the ever-changing drugs of abuse market. The company’s newly-established test for xylazine is the first immunoassay test in the world for this drug of abuse and is available on the Evidence MultiSTAT analyzer. Evidence MultiSTAT is designed to work across a variety of matrices including blood, and oral fluid, and simultaneously screens for up to 29 drugs of abuse from a single sample in less than 31 minutes.

In recent years, Randox has been expanding its Randox Health testing – bringing preventative healthcare directly to the public. Specializing in ‘Pre-disease’ highly sensitive biomarkers in the blood are measured before an individual start to feel sick and before regular blood tests would show illness. After making the service available throughout the UK and Ireland via its innovative mobile health clinic, Randox is now unveiling Randox Health Labs located in Santa Monica, California at AACC 2023. Randox’s extensive test menu offers over 150 analytes, allowing access some of the most specialized tests available in the market today.

Related Links:
Randox Laboratories 


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG
New
Nutating Mixer
Enduro MiniMix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.